Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Short term Debt: 2012-2025

Historic Short term Debt for Ptc Therapeutics (PTCT) over the last 9 years, with Sep 2025 value amounting to $286.3 million.

  • Ptc Therapeutics' Short term Debt rose 11.14% to $286.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $286.3 million, marking a year-over-year increase of 11.14%. This contributed to the annual value of $257.8 million for FY2024, which is 32.68% up from last year.
  • Per Ptc Therapeutics' latest filing, its Short term Debt stood at $286.3 million for Q3 2025, which was up 9.27% from $262.0 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Short term Debt ranged from a high of $286.3 million in Q3 2025 and a low of $33.1 million during Q1 2021.
  • Over the past 3 years, Ptc Therapeutics' median Short term Debt value was $248.2 million (recorded in 2025), while the average stood at $208.9 million.
  • Per our database at Business Quant, Ptc Therapeutics' Short term Debt surged by 611.32% in 2021 and then plummeted by 51.75% in 2022.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Short term Debt stood at $149.5 million in 2021, then plummeted by 51.75% to $72.1 million in 2022, then spiked by 169.32% to $194.3 million in 2023, then surged by 32.68% to $257.8 million in 2024, then rose by 11.14% to $286.3 million in 2025.
  • Its Short term Debt stands at $286.3 million for Q3 2025, versus $262.0 million for Q2 2025 and $248.2 million for Q1 2025.